X

Trial Profile

Safety and Immunogenicity of a Single Dose of Menactra Vaccine 4-6 Years After Prior Menactra Vaccine

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 23 Oct 2016

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Meningococcal vaccine groups A C Y W-135 conjugate (Primary)
Indications Meningococcal infections
Focus Pharmacodynamics; Registrational
Sponsors Sanofi Pasteur

Most Recent Events

15 Sep 2016 Results assessing safety and immunogenicity of booster dose published in the Vaccine (2016).
08 Sep 2014 Results published in the Media Release.
08 Sep 2014 Menactra was approved in the US for booster vaccination of subjects aged 15-55 years, based on results from this trial.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com